Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Filgotinib improves health-related quality of life in active PsA patients

21 Nov 2019

The oral, selective Janus kinase 1 inhibitor filgotinib confers a significant improvement in health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA), according to data from the phase II EQUATOR trial.

The trial randomized 131 patients to receive filgotinib 200 mg (n=65) or placebo (n=66) once daily for 16 weeks. All patients completed the Psoriatic Arthritis Impact of Disease (PsAID)9 questionnaire at weeks 4 and 16 to assess HRQoL.

Researchers evaluated the change from baseline in total and individual domain scores, in addition to the proportions of patients achieving minimal clinically important improvement (MCII; 3 points) and patient-accepted symptom status (PASS; score <4). They also examined the relationship between the PsAID9 and the 36-item short-form health survey (SF-36).

Filgotinib yielded significant improvements in PsAID9 total score compared with placebo, with the effect observable at week 4. At week 16, mean change in PsAID9 was greater with the active drug (–2.3 vs –0.8; least-squares mean of group difference, –1.48, 95 percent confidence interval [CI], –2.12 to –0.84; p<0.0001), with significant improvements in all individual domains vs placebo.

A greater percentage of patients treated with filgotinib vs placebo achieved MCII (group difference, 25.4, 95 percent CI, 8.92–39.99; p=0.0022) and PASS (group difference, 29.6 percent, 95 percent CI, 10.65–45.60; p=0.0018) at week 16. Comparable improvements in SF-36 were seen, and there was moderate to strong negative correlation between the SF-36 and PsAID9 scores.

The findings suggest that filgotinib rapidly improves multiple aspects of HRQoL that are relevant to patients with active PsA, as well as provide evidence concerning the usefulness of PsAID9 in measuring patient-relevant HRQoL domains in PsA clinical studies, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.